Sugi Predict

Sugi Predict / Compounds / SCHEMBL1615633

SCHEMBL1615633

SCHEMBL1615633

O=C(O)c1ccc2cncn2c1Nc1ccc(Br)cc1F

nearest known ligand 0.53

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ KCNH2 Q12809 4/20 0.53
▸ MAP2K1 Q02750 9/20 0.46
▸ CYP2C9 P11712 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ MAP2K2 P36507 2/20 0.39
▸ NPC1 O15118 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ IDO1 P14902 1/20 0.37
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ DGAT1 O75907 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21553375 0.90 KCNH2 (0.55) KCNH2MAP2K1CYP2C9GAAMAP2K2
SCHEMBL1616117 0.88 KCNH2 (0.53) KCNH2MAP2K1CYP2C9GAAMAP2K2
SCHEMBL16855006 0.86 KCNH2 (0.53) KCNH2MAP2K1CYP2C9MAP2K2
SCHEMBL1615638 0.86 KCNH2 (0.69) KCNH2MAP2K1CYP2C9MAP2K2IDO1
SCHEMBL29781392 0.86 KCNH2 (0.69) KCNH2MAP2K1CYP2C9MAP2K2IDO1
SCHEMBL2634095 0.84 CYP2C9 (0.53) KCNH2MAP2K1CYP2C9GAAMAP2K2
SCHEMBL1615873 0.84 KCNH2 (0.51) KCNH2MAP2K1CYP2C9MAP2K2IDO1
SCHEMBL1615838 0.83 KCNH2 (0.55) KCNH2MAP2K1CYP2C9GAAMAP2K2
SCHEMBL1616009 0.83 KCNH2 (0.50) KCNH2CYP2C9
SCHEMBL1615478 0.82 KCNH2 (0.80) KCNH2MAP2K1CYP2C9MAP2K2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2690101-B1 5-Anilinoimidazopyridines and Methods of Use GENENTECH INC (US) 2015-06-24 — — EP claimed
EP-2690101-A1 5-Anilinoimidazopyridines and Methods of Use Genentech, Inc. (US) 2014-01-29 — — EP claimed
EP-2222675-B1 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE GENENTECH INC (US) 2013-09-11 — — EP claimed
US-20120309765-A1 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE GENENTECH, INC. (US) 2012-12-06 — — US claimed
US-8288408-B2 5-anilinoimidazopyridines and methods of use GENENTECH, INC. (US) 2012-10-16 — — US claimed
US-20110158990-A1 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE GENENTECH, INC. (US) 2011-06-30 — — US claimed
US-10946093-B2 Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors GENENTECH, INC. (US) 2021-03-16 — — US disclosed
US-10646567-B2 Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors GENENTECH, INC. (US) 2020-05-12 — — US disclosed
EP-3563870-A1 METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS F. Hoffmann-La Roche AG (CH) 2019-11-06 — — EP disclosed
EP-3169361-B1 COMPOSITIONS FOR TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS HOFFMANN LA ROCHE (CH) 2019-06-19 — — EP disclosed
EP-2739358-B1 METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS HOFFMANN LA ROCHE (CH) 2018-11-28 — — EP disclosed
US-20180021431-A1 METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS GENENTECH, INC. (US) 2018-01-25 — — US disclosed
US-9724413-B2 Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors GENENTECH, INC. (US) 2017-08-08 — — US disclosed
US-7923456-B2 5-anilinoimidazo[1,5-a]-pyridines inhibitors of MEK kinase GENENTECH, INC. (US) 2011-04-12 — — US disclosed
EP-2222675-A1 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE Genentech, Inc. (US) 2010-09-01 — — EP disclosed
US-20100004269-A1 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE GENENTECH, INC. (US) 2010-01-07 — — US disclosed
US-20100004269-A1 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE GENENTECH, INC. (US) 2010-01-07 — — US disclosed
US-20100004269-A1 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE GENENTECH, INC. (US) 2010-01-07 — — US disclosed
WO-2009085983-A1 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE GENENTECH, INC. (US) 2009-07-09 — — WO disclosed
WO-2009085983-A1 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE GENENTECH, INC. (US) 2009-07-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10946093-B2 Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors CD274, PDCD1, PDCD1LG2 KCNH2 4598/4885MAP2K1 13/4885CYP2C9 4843/4885
US-10646567-B2 Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors CD274, PDCD1, PDCD1LG2 KCNH2 4598/4885MAP2K1 13/4885CYP2C9 4843/4885
US-20180021431-A1 METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS CD274, PDCD1, PDCD1LG2 KCNH2 4598/4885MAP2K1 13/4885CYP2C9 4843/4885
US-20120309765-A1 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE MKI67, PCNA, TYMP KCNH2 2040/4885MAP2K1 999/4885CYP2C9 3917/4885
US-20110158990-A1 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE MKI67, PCNA, TYMP KCNH2 2040/4885MAP2K1 999/4885CYP2C9 3917/4885
US-20100004269-A1 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE MKI67, MAP3K5, MAPKAPK5 KCNH2 1382/4885MAP2K1 64/4885CYP2C9 2665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.